- Home
- SFWL vs CSBR Comparison
SFWL vs CSBR Comparison
Compare SFWL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- CSBR
- Stock Information
- Founded
- SFWL 2001
- CSBR 1985
- Country
- SFWL China
- CSBR United States
- Employees
- SFWL N/A
- CSBR N/A
- Industry
- SFWL Trucking Freight/Courier Services
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SFWL Industrials
- CSBR Health Care
- Exchange
- SFWL Nasdaq
- CSBR Nasdaq
- Market Cap
- SFWL 82.5M
- CSBR 90.0M
- IPO Year
- SFWL 2023
- CSBR 1986
- Fundamental
- Price
- SFWL $0.91
- CSBR $6.85
- Analyst Decision
- SFWL
- CSBR Strong Buy
- Analyst Count
- SFWL 0
- CSBR 1
- Target Price
- SFWL N/A
- CSBR $12.00
- AVG Volume (30 Days)
- SFWL 6.9K
- CSBR 10.7K
- Earning Date
- SFWL 08-27-2025
- CSBR 12-10-2025
- Dividend Yield
- SFWL N/A
- CSBR N/A
- EPS Growth
- SFWL 31.68
- CSBR N/A
- EPS
- SFWL 0.14
- CSBR 0.21
- Revenue
- SFWL $540,461,000.00
- CSBR $56,878,000.00
- Revenue This Year
- SFWL N/A
- CSBR $7.31
- Revenue Next Year
- SFWL N/A
- CSBR $12.01
- P/E Ratio
- SFWL $6.48
- CSBR $31.94
- Revenue Growth
- SFWL 21.10
- CSBR 10.11
- 52 Week Low
- SFWL $0.84
- CSBR $4.07
- 52 Week High
- SFWL $1.38
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- SFWL 39.61
- CSBR 56.32
- Support Level
- SFWL $0.91
- CSBR $6.65
- Resistance Level
- SFWL $1.00
- CSBR $6.92
- Average True Range (ATR)
- SFWL 0.04
- CSBR 0.18
- MACD
- SFWL 0.00
- CSBR 0.02
- Stochastic Oscillator
- SFWL 43.09
- CSBR 79.46
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.